Novo Nordisk launches weekly insulin shot Awiqli in India
Novo Nordisk has launched Awiqli, a once-weekly basal insulin injection, in India to treat type 1 and type 2 diabetes. The product aims to improve patient compliance by significantly reducing the frequency of injections compared to daily options.
Why it matters
With over 100 million people living with diabetes in India, this medical innovation could significantly impact long-term disease management and the pharmaceutical market.
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday (July 9, 2026), aiming to compete with daily-dose options on the market.
The report is a factual business announcement regarding a product launch and market data.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in